[
  {
    "ts": null,
    "headline": "4 Best Value Stocks to Invest in This December for Strong Returns",
    "summary": "Value investing is essentially about selecting stocks that are cheap but fundamentally sound. TSN, AXS, PFE & GM boast a low P/CF ratio.",
    "url": "https://finnhub.io/api/news?id=abc646035736dc803aed448e899005cc293cd86f5c8dccf4fb4057f7f9c669a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732910400,
      "headline": "4 Best Value Stocks to Invest in This December for Strong Returns",
      "id": 131714125,
      "image": "https://media.zenfs.com/en/zacks.com/d1aa21e7f6aae9026b3da3c20c2cfea4",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Value investing is essentially about selecting stocks that are cheap but fundamentally sound. TSN, AXS, PFE & GM boast a low P/CF ratio.",
      "url": "https://finnhub.io/api/news?id=abc646035736dc803aed448e899005cc293cd86f5c8dccf4fb4057f7f9c669a5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=19af42a805edc8a8312ca5dfc2506bc873537dbbe476b3b08a798198a39b49cb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732898400,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 131777352,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=19af42a805edc8a8312ca5dfc2506bc873537dbbe476b3b08a798198a39b49cb"
    }
  },
  {
    "ts": null,
    "headline": "RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma",
    "summary": "Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma.",
    "url": "https://finnhub.io/api/news?id=2313156941b1714cf117a672eb6c087b35125c1cdc80621516f6d1c0072f26f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732892940,
      "headline": "RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma",
      "id": 131712739,
      "image": "https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma.",
      "url": "https://finnhub.io/api/news?id=2313156941b1714cf117a672eb6c087b35125c1cdc80621516f6d1c0072f26f7"
    }
  },
  {
    "ts": null,
    "headline": "How Much Would It Take To Earn $100 A Month From Pfizer Stock?",
    "summary": "Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United States, Europe and internationally. It will report its Q4 2024 earnings on Jan. 28, 2025. Wall Street analysts expect the ...",
    "url": "https://finnhub.io/api/news?id=77df27f9fc5d52514ed602e57de18abd1d3aedc95f7b3004bc49464e1a35ac73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732888815,
      "headline": "How Much Would It Take To Earn $100 A Month From Pfizer Stock?",
      "id": 131712740,
      "image": "https://media.zenfs.com/en/benzinga_79/71fdfbd4696d0d34a6b1b211739ac187",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United States, Europe and internationally. It will report its Q4 2024 earnings on Jan. 28, 2025. Wall Street analysts expect the ...",
      "url": "https://finnhub.io/api/news?id=77df27f9fc5d52514ed602e57de18abd1d3aedc95f7b3004bc49464e1a35ac73"
    }
  },
  {
    "ts": null,
    "headline": "Is This a New Reason to Buy Pfizer Stock Hand Over Fist?",
    "summary": "Despite Pfizer's (NYSE: PFE) recent struggles with falling earnings and a bid by an activist investor to unseat its leadership, the pharma juggernaut is still actively advancing its core priorities and giving investors plenty of reasons to consider buying its stock while it's cheap.  On Nov. 20, Pfizer announced that its strategic partnership with Flagship Pioneering, a highly prestigious biopharma venture capital (VC) group, had agreed on a new collaboration.  Per the agreement, one of Flagship's portfolio companies, a private biotech called Ampersand Biomedicines, will work with Pfizer to potentially develop new medicines for obesity.",
    "url": "https://finnhub.io/api/news?id=b847a0d22ce64ea0c33b9a7ff67328748961967696af8d4cd607273d9adc6f3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732887900,
      "headline": "Is This a New Reason to Buy Pfizer Stock Hand Over Fist?",
      "id": 131712741,
      "image": "https://g.foolcdn.com/editorial/images/799006/three-scientists-work-in-laboratory-with-one-looking-down-a-microscope.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Despite Pfizer's (NYSE: PFE) recent struggles with falling earnings and a bid by an activist investor to unseat its leadership, the pharma juggernaut is still actively advancing its core priorities and giving investors plenty of reasons to consider buying its stock while it's cheap.  On Nov. 20, Pfizer announced that its strategic partnership with Flagship Pioneering, a highly prestigious biopharma venture capital (VC) group, had agreed on a new collaboration.  Per the agreement, one of Flagship's portfolio companies, a private biotech called Ampersand Biomedicines, will work with Pfizer to potentially develop new medicines for obesity.",
      "url": "https://finnhub.io/api/news?id=b847a0d22ce64ea0c33b9a7ff67328748961967696af8d4cd607273d9adc6f3f"
    }
  },
  {
    "ts": null,
    "headline": "Black Friday Sale for Income Investors: These 3 Ultra-High-Yield Dividend Stocks Are Bargain Buys",
    "summary": "Are there any Black Friday sales for income investors?  Here are three ultra-high-yield dividend stocks that are bargain buys.  What better to put you in the holiday spirit than a juicy forward dividend yield of around 8.7%?",
    "url": "https://finnhub.io/api/news?id=cce55b3aee685792fc69860077d92da518048b062caa32cd0668bf9e8bf1f8a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732873980,
      "headline": "Black Friday Sale for Income Investors: These 3 Ultra-High-Yield Dividend Stocks Are Bargain Buys",
      "id": 131702820,
      "image": "https://g.foolcdn.com/editorial/images/798983/sale-sign-woman-holding-megaphone.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Are there any Black Friday sales for income investors?  Here are three ultra-high-yield dividend stocks that are bargain buys.  What better to put you in the holiday spirit than a juicy forward dividend yield of around 8.7%?",
      "url": "https://finnhub.io/api/news?id=cce55b3aee685792fc69860077d92da518048b062caa32cd0668bf9e8bf1f8a5"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary",
    "summary": "The Janus Henderson Global Life Sciences Diversified ADR Managed AccountÂ Portfolio returned 5.74% (gross) for Q3 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=d13820debe5090781df5f64d03a4e6366609fc54e420fcea29eb851f7981fff8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732841400,
      "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary",
      "id": 131700113,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1633433467/image_1633433467.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The Janus Henderson Global Life Sciences Diversified ADR Managed AccountÂ Portfolio returned 5.74% (gross) for Q3 2024. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=d13820debe5090781df5f64d03a4e6366609fc54e420fcea29eb851f7981fff8"
    }
  }
]